Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) is an emerging biopharmaceutical company formed to acquire, license, and develop existing novel therapies which have substantial commercialization potential. Omni is the licensee of issued and pending patents from the University of Colorado Denver. Omni has been advancing broad-spectrum therapeutics targeting bacterial and viral diseases, biohazards, diabetes and transplant rejection since February 2006. The Company's core technology is based on novel discoveries made at the University of Colorado involving therapeutic agents already approved for use in humans.
Recent News
- Dr. Charles A. Dinarello of the University of Colorado and Acting CEO of Omni Bio Pharmaceutical to be Awarded the Paul Ehrlich Prize (10/02/09)
- Omni Bio Pharmaceutical to Present at Accredited Members Fall 2009 Micro Cap/Small Cap Confrence (9/22/09)
- Omni Bio Pharmaceutical Announces Ticker Symbol Change to OMBP (7/20/09)
- Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board (6/24/09)
- Omni Bio Pharmaceutical, Inc. Completes Name Change and Announces Managerial Appointments and Position Changes (6/02/09)
- Dr. Charles A. Dinarello Co-Awarded Largest US Prize in Medical Research, the Albany Medical Center Prize in Medicine and Biomedical Research (4/29/09)
- Across America Financial Services Completes Acquisition of Apro Bio Pharmaceutical Corporation (4/20/09)
